Phase 2 AMG 714 in Rheumatoid Arthritis

Amgen

Status and phase: Completed; Phase 2

Conditions: Rheumatoid Arthritis

Treatments: Drug: AMG 714

Study type: Interventional

Funder types: Industry

Identifiers

NCT00433875

20030210

Details and patient eligibility

About

Twelve week treatment of AMG 714 in RA patients who failed at least one DMARD, followed by a 3 month observational period.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Diagnosis of RA -

Exclusion Criteria: No prior biologic treatment for RA

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind